Immatics Biotechnologies

Activities: Regulatory Research & Development Pharmaceutical

Trending Articles

  1. AstraZeneca invests $3.5bn into its US pharmaceutical research and manufacturing capabilities The company will expand its biologics manufacturing, as well as its speciality manufacturing and cell therapy production capacity, while also extending its pharmaceutical...
  2. The importance of accurate tare/gross weighing systems in the pharmaceutical industry Why accurate tare/gross weighing is critical in pharmaceutical settings
  3. IMed Consultancy enabling innovation in the mental healthcare sector with Limbic Limbic is a London-based start-up that is using world-leading, clinically validated Artificial Intelligence and beautiful product design to make psychological therapy...
  4. Romaco showcases its solid dosage processing portfolio at CPHI & PMEC India The company will display its portfolio suitable for the granulation, tableting, and coating of pharmaceutical solids
  5. Lonza expands bioconjugation capabilities for ADC manufacturing at Visp site The CDMO's facility will double its bioconjugate manufacturing capacity with two 1,200 L manufacturing suites

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

Related Content

Recruitment

Immatics appoints Chief Medical Officer

Recruitment

Immatics appoints Thomas Ulmer as Chief Financial Officer
Research & Development

Amgen and Immatics enter strategic collaboration to develop novel bispecific cancer immunotherapies

Immatics to receive $30 million upfront and potentially more than $1 billion in milestone payments plus royalties
Research & Development

MorphoSys and Immatics Biotechnologies sign immuno-oncology agreement

To develop antibody based therapies against multiple cancers
Research & Development

EU-funded consortium to advance personalised cancer vaccines into trials

First centres to enrol glioblastoma patients are opened in Heidelberg and Tuebingen in Germany

Cancer vaccine – IMA901/IMA910

Therapeutic vaccines may prove both effective and directed as cancer treatments
Regulatory

Immatics and Cancer Research UK to develop brain cancer vaccine

Immatics Biotechnologies, a German clinical-stage biopharmaceutical company, is to collaborate with Cancer Research UK on the further development of Immatics" therapeutic cancer vaccine IMA950 in glioblastoma, the most aggressive form of brain cancer.
Subscribe now